| Targeting MYC dependence in cancer by inhibiting BET bromodomains JA Mertz, AR Conery, BM Bryant, P Sandy, S Balasubramanian, DA Mele, ... Proceedings of the National Academy of Sciences 108 (40), 16669-16674, 2011 | 1280 | 2011 |
| Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma JJ Keats, R Fonseca, M Chesi, R Schop, A Baker, WJ Chng, S Van Wier, ... Cancer cell 12 (2), 131-144, 2007 | 1212 | 2007 |
| Characterizing gene sets with FuncAssociate GF Berriz, OD King, B Bryant, C Sander, FP Roth Bioinformatics 19 (18), 2502-2504, 2003 | 597 | 2003 |
| Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib G Mulligan, C Mitsiades, B Bryant, F Zhan, WJ Chng, S Roels, E Koenig, ... Hematology 63, 2005 | 461 | 2005 |
| Mapping of a gene for type 2 diabetes associated with an insulin secretion defect by a genome scan in Finnish families MM Mahtani, E Widén, M Lehto, J Thomas, M McCarthy, J Brayer, ... Nature genetics 14 (1), 90-94, 1996 | 419 | 1996 |
| Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling WJ Chng, S Kumar, S VanWier, G Ahmann, T Price-Troska, K Henderson, ... Cancer research 67 (7), 2982-2989, 2007 | 310 | 2007 |
| ART 1 and pattern clustering B Moore Proceedings of the 1988 connectionist models summer school, 174-185, 1989 | 299 | 1989 |
| BET bromodomain inhibition suppresses TH17-mediated pathology DA Mele, A Salmeron, S Ghosh, HR Huang, BM Bryant, JM Lora Journal of experimental medicine 210 (11), 2181-2190, 2013 | 254 | 2013 |
| AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development SN Khleif, JH Doroshow, WN Hait Clinical Cancer Research 16 (13), 3299-3318, 2010 | 230 | 2010 |
| Identification of cervical cancer markers by cDNA and tissue microarrays Y Chen, C Miller, R Mosher, X Zhao, J Deeds, M Morrissey, B Bryant, ... Cancer research 63 (8), 1927, 2003 | 214 | 2003 |
| EZH2 inhibitor efficacy in non-Hodgkin’s lymphoma does not require suppression of H3K27 monomethylation WD Bradley, S Arora, J Busby, S Balasubramanian, VS Gehling, ... Chemistry & biology 21 (11), 1463-1475, 2014 | 164 | 2014 |
| A quantitative atlas of histone modification signatures from human cancer cells G LeRoy, PA DiMaggio, EY Chan, BM Zee, MA Blanco, B Bryant, ... Epigenetics & chromatin 6, 1-14, 2013 | 151 | 2013 |
| The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition WJ Chng, E Braggio, G Mulligan, B Bryant, E Remstein, R Valdez, ... Blood, The Journal of the American Society of Hematology 111 (3), 1603-1609, 2008 | 145 | 2008 |
| An alternative approach to ChIP-Seq normalization enables detection of genome-wide changes in histone H3 lysine 27 trimethylation upon EZH2 inhibition B Egan, CC Yuan, ML Craske, P Labhart, GD Guler, D Arnott, TM Maile, ... PloS one 11 (11), e0166438, 2016 | 140 | 2016 |
| Discovery, design, and optimization of isoxazole azepine BET inhibitors VS Gehling, MC Hewitt, RG Vaswani, Y Leblanc, A Côté, CG Nasveschuk, ... ACS medicinal chemistry letters 4 (9), 835-840, 2013 | 124 | 2013 |
| Methods for the identification, assessment, and treatment of patients with cancer therapy BM Bryant, AI Damokosh, G Mulligan US Patent 8,278,038, 2012 | 123* | 2012 |
| Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma AR Conery, RC Centore, A Neiss, PJ Keller, S Joshi, KL Spillane, ... Elife 5, e10483, 2016 | 113 | 2016 |
| Pharmacological inhibition of the histone lysine demethylase KDM1A suppresses the growth of multiple acute myeloid leukemia subtypes JP McGrath, KE Williamson, S Balasubramanian, S Odate, S Arora, ... Cancer research 76 (7), 1975-1988, 2016 | 103 | 2016 |
| High-risk myeloma: A gene expression–based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed … F Zhan, B Barlogie, G Mulligan, JD Shaughnessy Jr, B Bryant Blood 111 (2), 968-969, 2008 | 83 | 2008 |
| Assessment of chromosomal alterations to predict clinical outcome of bortezomib treatment BM Bryant, H Danaee, GJ Mulligan US Patent App. 12/454,944, 2010 | 77 | 2010 |
Peter Leif BergsagelMayo Clinic in ArizonaПодтвержден адрес электронной почты в домене mayo.edu
